Yibin Kang in his lab

Yibin Kang awarded American Cancer Society research professorship grant

By Courtesy of the American Cancer Society on Nov. 1, 2019, 9 a.m.

Yibin Kang

Photo by
Denise Applewhite, Office of Communications

Yibin Kang, Ph.D., the Warner-Lambert/Parke Davis Professor of Molecular Biology at Princeton University and the associate director for Consortium Research of Rutgers Cancer Institute of New Jersey, has been awarded an American Cancer Society Research Professorship, receiving a lifelong designation accompanied by a five-year $400,000 commitment.

Kang’s research focuses on the molecular mechanisms driving breast cancer metastasis, in particular exploring how the body's connective tissue cells, or stromal cells, provide cellular “niches” that allow cancer cells to metastasize. The new grant will build on the team’s study of tumor-stromal interactions in breast cancer bone metastasis and is expected to have important implications in improving the treatment of metastatic breast cancer.

Researchers are selected for American Cancer Society (ACS) professorships based on their history of pioneering, influential work that’s continuing to change the direction of cancer research and on their track record of mentoring people who have become successful in cancer research.

“Research remains at the heart of our mission,” said Arnold Baskies, MD, American Cancer Society past chairman of the National Board of Directors. “Dr. Kang’s research specifically focused on metastasis is crucial to find answers into new or improved treatments and therapies.”

As of Jan. 1, 2019, there were more than 3.8 million women with a history of breast cancer living in the United States, according to the ACS. This estimate includes more than 150,000 women living with metastatic disease, three-quarters of whom were originally diagnosed with stage I, II or III breast cancer.

“Laboratory research and clinical experience have repeatedly highlighted the importance of the stromal cells in the development and treatment response of metastatic cancers,” said Kang. “Our research focuses on identifying the key components and molecular interactions that are critical for breast cancer metastasis. Our findings will facilitate the development of novel therapeutics to reduce the risk of metastatic recurrence or improve the survival of patients with metastatic diseases." 

“This lifetime recognition by the American Cancer Society of Yibin Kang’s outstanding research accomplishments highlights the importance of the ongoing collaboration between researchers such as Dr. Kang, who studies the fundamental mechanisms behind cancer, and the translational researchers and clinicians at the Rutgers Cancer Institute of New Jersey,” said Princeton University Dean for Research Pablo Debenedetti. “The support from ACS is an important contribution to collaborative research with the potential to have tremendous impact on the prevention and treatment of this disease.”

“Rutgers Cancer Institute and Princeton University, our National Cancer Institute-approved research consortium partner, have worked collaboratively for many years to address the cancer burden,” noted Eileen White, Ph.D., deputy director, chief scientific officer and associate director for basic research at Rutgers Cancer Institute of New Jersey.  As a result of this partnership and Dr. Kang’s leadership of this consortium, essential scientific discoveries in the areas of cancer metabolism, metastasis and genomics have been translated into clinical application.”

Kang's award is one of three new Research Professorships — the program's prestigious research grants — announced by the ACS, which is the largest private, nonprofit source of cancer research funds in the United States. Kang was a recipient of the ACS Research Scholar Award in 2005.

Related Stories

Research team targets self-cannibalizing cancer cells .

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

Team finds breast cancer gene linked to disease spread .

A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.

A new weapon against bone metastasis? Princeton lab develops antibody to fight cancer .

A new antibody developed by Princeton researchers fights bone metastasis by undermining cancer's defense strategy and allowing chemotherapy to work.

Ludwig Institute for Cancer Research and Princeton University partner to ‘push the frontiers’ on diet, metabolism and cancer .

The Ludwig Princeton Branch will bring the University’s world-leading technologies to the cutting edge of cancer research.

Scientists discover mechanism involved in breast cancer's spread to bone .

In a discovery that may lead to a new treatment for breast cancer that has spread to the bone, a Princeton University research team has unraveled a mystery about how these tumors take root. What the Princeton research has uncovered is the exact mechanism that lets traveling tumor cells disrupt normal bone growth.

Princeton scientists discover an interaction that helps cancers spread to bone .

A Princeton-led team of researchers has discovered a factor that promotes the spread of cancers to bone, opening the way toward treatments that could mitigate cancer’s ability to metastasize.

New cancer therapy from Yibin Kang's lab holds potential to switch off major cancer types without side effects .

In mice and in human tissue, a new compound discovered at Princeton disables a key gene that’s implicated in breast, prostate, liver, lung, colon and other cancers.